Editas Medicine shares edge higher after Q4 earnings and revenue top estimates
The article reports that Editas Medicine (EDIT) shares saw a modest increase after the company announced its Q4 earnings and revenue exceeded analyst expectations.
EDIT Should I Buy
Editas Medicine Inc (EDIT) is not recommended as a strong buy for beginner or long-term investors due to weak financial performance, despite positive catalysts like a patent dispute win and increasing hedge fund interest. Revenue, net income, and EPS have seen significant year-over-year declines, and technical indicators suggest a neutral trend. Analysts hold mixed views, with one upgrade to 'Buy' and another downgrade while maintaining a 'Buy' rating.
Editas Medicine Inc Stock: Genome Editing Pioneer Faces Key Milestones in Competitive Biotech Landsc
Editas Medicine Inc, a pioneer in CRISPR-based genome editing, continues to advance its drug pipeline despite sector challenges, with key programs targeting ocular, blood, and other disorders. The company, through its proprietary CRISPR/Cas9 platform, aims to develop one-time, curative treatments for inherited disorders, driven by a robust intellectual property portfolio and strategic partnerships. While facing intense competition and high risks typical of biotech, Editas's progress in clinical trials and potential partnerships represent critical inflection points for investors, particularly given its current market capitalization of $244 million and analyst forecasts suggesting upside potential.
Editas Medicine Inc Stock: Genome Editing Pioneer Faces Key Milestones in Competitive Biotech Landsc
Editas Medicine Inc, a leader in CRISPR-based genome editing, is advancing its pipeline to address genetic diseases with its precise CRISPR/Cas9 platform. The company faces significant milestones with upcoming clinical data readouts and operates in a competitive biotech landscape against peers like CRISPR Therapeutics and Intellia Therapeutics. North American investors are keen on potential catalysts and strategic partnerships, despite the inherent risks and high volatility associated with development-stage biotech firms.
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program
Editas Medicine Inc. (EDIT) has confirmed EDT-401 as its lead in vivo program. This announcement highlights the company's focus on advancing this specific therapeutic candidate in its pipeline.
Editas Medicine Inc Stock: Gene Editing Pioneer Faces Clinical and Market Hurdles in Biotechnology L
Editas Medicine Inc, a leader in CRISPR-based gene editing, is navigating clinical development challenges and competitive market hurdles. The company's lead program, EDIT-301, targets beta-thalassemia and sickle cell disease, showing promising preclinical data. Editas faces stiff competition from peers but differentiates itself through its broad patent estate and focus on both ex vivo and in vivo applications, continually striving to overcome technical and market obstacles in the promising field of gene therapy.
Editas Medicine Inc Stock: Gene Editing Pioneer Faces Clinical and Market Hurdles in Biotechnology Landscape
Editas Medicine Inc, a leader in CRISPR-based gene editing, is navigating clinical development challenges and market hurdles despite its innovative technology. The company's lead program, EDIT-301, targets sickle cell disease and beta-thalassemia, with additional programs in ophthalmology and immuno-oncology. Analysts maintain a "hold" rating, reflecting the inherent risks and long-term potential in biotechnology investing, with success heavily dependent on clinical trial outcomes and competitive positioning.
CRISPR patent win bolsters Editas Medicine (NASDAQ: EDIT) IP estate
Editas Medicine announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s decision favoring the Broad Institute in a key CRISPR/Cas9 patent interference, strengthening Editas's intellectual property estate. This ruling, the third such decision, confirms Broad as the first to invent CRISPR/Cas9 use in eukaryotic cells, with Editas holding exclusive licenses for these patents in medicine. The company highlighted that this reinforces confidence as they advance in vivo gene editing programs, including EDIT-401, which has shown significant LDL cholesterol reduction in non-human primates.
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Editas Medicine announced that the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) reaffirmed its decision favoring the Broad Institute in a CRISPR/Cas9 gene editing patent interference case. This is the third time PTAB has ruled that Broad was the first to invent the use of CRISPR/Cas9 in eukaryotic cells, including human cells. Editas Medicine, which exclusively licenses the CRISPR/Cas9 patents at issue, expressed confidence in its intellectual property and its ongoing development of gene-editing medicines.
USPTO Reaffirms Broad Institute’s Patents in CRISPR/Cas9 Dispute
The United States Patent and Trademark Office (USPTO) has reaffirmed its decision in favor of the Broad Institute regarding its CRISPR/Cas9 patents, as announced by Editas Medicine. This ruling confirms the Broad Institute's ownership of key foundational patents for the gene-editing technology, despite the ongoing intellectual property dispute with competing claims. Editas Medicine stated its continued commitment to genome editing advancements following this significant determination in the legal battle over CRISPR/Cas9 rights.
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Editas Medicine announced that the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) reaffirmed its decision favoring the Broad Institute in a CRISPR/Cas9 patent interference case. This ruling reinforces Broad's inventorship priority for gene editing in eukaryotic cells, including human cells. Editas Medicine, which exclusively licenses these CRISPR/Cas9 patents, expressed confidence in its intellectual property and its ongoing development of transformative gene editing medicines.
Editas Medicine Announces U.S. Patent and Trademark Office
Editas Medicine announced that the U.S. Patent and Trademark Office reaffirmed its decision favoring the Broad Institute in a CRISPR/Cas9 patent interference case, reinforcing Broad's inventorship priority for gene editing in eukaryotic cells. This decision validates Editas Medicine's intellectual property, which exclusively licenses these patents for developing CRISPR/Cas9-based medicines. The company plans to leverage this to advance its in vivo gene editing therapies, including EDIT-401, for serious diseases.
A key U.S. CRISPR patent fight swings again toward Editas partner Broad
Editas Medicine announced that the U.S. Patent and Trademark Office reaffirmed its prior decision favoring the Broad Institute in the CRISPR/Cas9 interference case. This marks the third time the PTAB has found Broad to be the first to invent CRISPR/Cas9 in eukaryotic cells. Editas, which exclusively licenses the patents at issue, states that its broader CRISPR intellectual property portfolio remains intact, although CVC retains the right to appeal to the CAFC.
Editas Medicine Announces U.S. Patent and Trademark Office
Editas Medicine announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s decision in favor of the Broad Institute regarding CRISPR/Cas9 editing in human cells. This marks the third favorable decision for Broad, asserting their inventorship priority for CRISPR/Cas9 gene editing in eukaryotic cells. Editas Medicine, as an exclusive licensee of these patents, expressed confidence in its intellectual property and its ongoing development of gene-editing medicines.
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Editas Medicine announced that the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) reaffirmed its decision favoring the Broad Institute in a CRISPR/Cas9 patent interference case. This is the PTAB's third decision recognizing Broad as the first to invent the use of CRISPR/Cas9 for gene editing in human cells. Editas Medicine, which exclusively licenses these patents, stated this outcome reinforces their confidence in their intellectual property for developing transformative gene-editing medicines.
EDITAS MEDICINE Operating Margin %: -56.65% | Fairly Valued
This article analyzes Editas Medicine's (NAS:EDIT) operating margin, which stands at -56.65% as of December 2025. GuruFocus rates EDIT with a GF Score of 63/100 and considers it "Fairly Valued" at a price of $2.32 against a GF Value of $2.51, despite having 7 warning signs. The article details the calculation of operating margin and emphasizes its importance as an indicator of a company's operational efficiency and potential financial issues, especially when declining over time.
If You Invested $1,000 in Editas Medicine Inc (EDIT)
This article analyzes the historical performance of an imaginary $1,000 investment in Editas Medicine Inc (EDIT) over one, five, and ten years. It details the company's focus on in vivo CRISPR-based gene editing, its lead candidate EDIT-401 for hyperlipidemia, and its collaborations. The financial data reveals significant volatility and underperformance compared to the S&P 500 over longer periods, despite a recent one-year gain.
Editas Medicine, Inc. Trade Ideas — LS:A2AC4K
This article compiles various trading ideas and technical analyses for Editas Medicine, Inc. (LS:A2AC4K, NASDAQ:EDIT) shared by traders on TradingView. The ideas range from long positions based on technical indicators and potential breakthroughs in gene editing to short-term trading strategies and accumulation plays for upcoming events. Most analyses express bullish sentiment, highlighting support levels, breakouts, and future growth potential for the biotech company.
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Moderate Buy" from Analysts
Editas Medicine, Inc. (EDIT) has received a consensus "Moderate Buy" rating from analysts, with an average one-year target price of $5.30. The company recently reported better-than-expected earnings per share of ($0.06) and revenue of $24.74 million, significantly beating analyst estimates. Institutional investors have increased their holdings, now owning approximately 71.9% of the stock.
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT)
This article provides analyst insights on three healthcare companies: Perspective Therapeutics (CATX), DocGo (DCGO), and Editas Medicine (EDIT). Perspective Therapeutics holds a Strong Buy consensus with a significant upside, while DocGo also has a Strong Buy rating with a high potential upside. Editas Medicine, however, maintains a Hold consensus rating.
Editas Medicine (EDIT) Stock: 5-Year Valuation Drop & Recent Pipeline Challenges - News and Statistics
Editas Medicine (NASDAQ: EDIT) has seen its stock price increase over the past year despite a significant five-year decline in market valuation. The clinical-stage biotechnology firm, which focuses on gene editing, faces commercial challenges due to the high costs and complexity of its therapies. The company has also experienced multiple pipeline setbacks, including pausing development for two rare eye conditions (EDIT-101 and EDIT-103) and discontinuing a blood disorder treatment due to failure to secure a commercial partner.
Is Editas Medicine Going to $0?
Editas Medicine (NASDAQ: EDIT), a small-cap biotech, has seen its shares soar by 80% over the past 12 months, but it has lost over 90% of its market value in the last five years. The company faces significant challenges as a clinical-stage and gene-editing specialist, with a history of pipeline setbacks and abandoned drug candidates like EDIT-101, EDIT-103, and reni-cel due to a lack of commercial partners. With all its remaining programs in early stages and no late-stage clinical trials, the author believes the stock will continue to decline, recommending investors avoid it.
Is Editas Medicine Going to $0?
Editas Medicine, a small-cap biotech company specializing in gene editing, has seen its stock soar by 80% in the last 12 months but has lost over 90% of its market value in the past five years. The article highlights the company's "terrible track record" with several pipeline setbacks and abandoned drug candidates, such as EDIT-101, EDIT-103, and reni-cel, primarily due to an inability to find commercial partners. The author concludes that Editas Medicine's prospects are dim, especially given that its remaining programs are in early stages, making its stock likely to continue declining toward $0.
Editas Medicine (EDIT) grants 292,856 stock options to chief scientific officer
Editas Medicine, Inc. (EDIT) has granted its EVP and Chief Scientific Officer, Linda Burkly, 292,856 stock options. The options have an exercise price of $2.54 per share and will vest monthly over four years, aligning her long-term incentives with the company's performance. This grant was reported via an SEC Form 4 filing on March 16, 2026.
Is Editas Medicine Headed Toward Zero?
Shares of Editas Medicine (NASDAQ: EDIT) have seen an 80% increase in the past year, but a five-year perspective shows a more than 90% decline. As a clinical-stage biotech company with no approved products and a history of stalled or abandoned projects, including EDIT-101, EDIT-103, and Reni-cel, the company faces significant risks. The article advises investors to be cautious given its early-stage pipeline and past disappointments.
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Ascend Wellness Holdings LLC (OtherAAWH)
J.P. Morgan analyst Brian Cheng maintained a Sell rating on Editas Medicine (EDIT) with a price target of $5.15, while Ascend Wellness Holdings LLC (AAWH) received a Buy rating from Haywood analyst Neal Gilmer with a price target of C$1.00. Both companies operate in the healthcare sector, and analysts have provided varying outlooks based on their assessments.
Editas Medicine (EDIT) Q3 Loss Improvement Tests Bearish Earnings Decline Narrative
Editas Medicine (EDIT) reported a Q3 FY2025 revenue of US$7.5 million and a basic EPS loss of US$0.28, marking an improvement in net income loss for the quarter. Despite this, the company remains unprofitable with a trailing 12-month net loss of US$199.8 million and less than a year of cash runway, leading to mixed investor sentiment between projected revenue growth and ongoing profitability concerns. The stock trades at a P/S ratio of 4.9x, which is above its peer average but below the broader biotech industry, reflecting the debate around its valuation given its financial outlook.
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates
Editas Medicine (EDIT) reported a smaller-than-expected loss in Q4 2025 with revenue exceeding estimates. The company provided its 2026 financial outlook, projecting a net cash usage between $170M and $190M. This positive financial update led to a slight increase in share price after hours.
Editas Medicine (EDIT) Receives Upgrade to 'Buy' from Jones Trading
Jones Trading has upgraded Editas Medicine (EDIT) from a 'Hold' to a 'Buy' rating, setting a new price target of $8.00. This upgrade signals increased optimism for the genome editing company. Other analysts have also maintained or raised their ratings and price targets for EDIT recently.
Editas Medicine (EDIT) Receives Upgrade to 'Buy' from Jones Trading | EDIT Stock News
Jones Trading has upgraded Editas Medicine (EDIT) from 'Hold' to 'Buy', setting a new price target of $8.00. This upgrade reflects increased optimism for the company, whose average analyst target price is $5.21, implying a potential 99.40% upside from its current price. Editas Medicine is a clinical-stage genome editing company focused on developing CRISPR/Cas9 technology for treating serious diseases.
Editas Medicine (NASDAQ:EDIT) Upgraded at JonesTrading
JonesTrading upgraded Editas Medicine (NASDAQ:EDIT) from a "hold" to a "buy" rating with an $8.00 target price, implying a significant upside. This upgrade follows the company's better-than-expected Q4 results, where it reported an EPS of -$0.06 against a consensus of -$0.27 and revenue of $24.74 million versus an $8.77 million estimate. Despite the positive news, the company remains unprofitable with negative margins and ROE.
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y
Editas Medicine (EDIT) reported a narrower-than-expected loss of 6 cents per share in Q4 2025 and revenues of $24.7 million, significantly beating analyst estimates. This positive quarterly performance, driven by lower operating expenses, led to a 16% rise in Editas shares. The company is focusing on in vivo pipeline development, with EDIT-401 as its lead candidate, aiming for an investigational new drug application by mid-2026.
Editas Medicine (EDIT) Q3 Loss Improvement Tests Bearish Earnings Decline Narrative
Editas Medicine (EDIT) reported Q3 2025 revenue of US$7.5 million and narrowed its net income loss to US$25.1 million, an improvement from previous quarters. Despite this, the company's trailing 12-month basic EPS loss is US$2.35 and net income loss is US$199.8 million, with forecasts indicating continued unprofitability and a decline in earnings over the next three years. Although revenue is projected to grow by 20.24% annually, the company faces a tight cash runway of less than one year, leading to a mixed outlook for investors.
Editas Medicine (NASDAQ: EDIT) pivots to in vivo CRISPR and monetizes IP
Editas Medicine (NASDAQ: EDIT) is shifting its strategic focus to in vivo CRISPR gene editing, with its lead candidate EDIT-401 targeting hyperlipidemia by upregulating LDL receptors. The company is actively monetizing its intellectual property, exemplified by licensing its Cas9 technology to Vertex Pharmaceuticals for sickle cell disease and beta thalassemia, and further monetizing future license fees through an agreement with DRI Healthcare Trust. This strategic pivot aims to accelerate human proof-of-concept for its in vivo therapies and optimize its cost structure.
Editas Medicine 10-K: $40.5M revenue, $(1.80) EPS
Editas Medicine (EDIT) reported $40.5 million in collaboration and other R&D revenues for the year, alongside a net loss per share of $(1.80). The company's financial performance showed improvement with a reduced operating loss of $(160.0) million and a net loss of $(160.1) million, driven by lower operating expenses and a strategic refocus. Editas has nominated EDIT-401 as its lead in vivo candidate, planning an IND filing for mid-2026, and significantly reduced its workforce to concentrate resources on this program and LNP delivery platforms.
Editas Medicine stock rises 2% after Q4 earnings and revenue beats
Editas Medicine (NASDAQ:EDIT) exceeded analyst expectations in its fourth-quarter earnings report, posting a narrower loss per share and significantly higher revenue than estimated. The company's shares rose 2% in pre-market trading, driven by reduced R&D and general administrative expenses, and progress on its gene editing pipeline including EDIT-401 for familial hypercholesterolemia. Editas expects its current cash to fund operations into Q3 2027 and aims for early human proof-of-concept data for EDIT-401 by year-end 2026.
Editas Medicine (NASDAQ:EDIT) Receives "Buy" Rating from Chardan Capital
Chardan Capital has reaffirmed its "Buy" rating for Editas Medicine (NASDAQ:EDIT), setting a price target of $3.50, which suggests a 51.8% upside. This comes after Editas Medicine surpassed Q3 earnings and revenue expectations, despite remaining unprofitable with a negative net margin. The company holds a "Moderate Buy" consensus rating from analysts with an average target price of $4.63.
Editas: Q4 Earnings Snapshot
Editas Medicine Inc. (EDIT) reported a smaller-than-expected loss of $5.6 million, or 6 cents per share, in its fourth quarter, surpassing Wall Street expectations for a loss of 27 cents per share. The genome editing company also exceeded revenue forecasts, reporting $24.7 million compared to an expected $6.5 million. For the full year, Editas posted a loss of $160.1 million and revenue of $40.5 million.
BREAKING: EDIT Reports Narrower Loss for Q4 EPS, vs. $0.21 per share estimated
Editas Medicine (EDIT) reported a narrower-than-expected loss of $0.06 per share for Q4 2025, significantly outperforming the consensus estimate of a $0.21 loss. The biotechnology company achieved $24.74 million in revenue for the quarter. Following the earnings release, shares of Editas Medicine traded at $1.90 on NASDAQ.
Editas: Fourth Quarter Financial Overview
Editas Medicine Inc. reported a net loss of $5.6 million, or $0.06 per share, for the fourth quarter, which was better than the $0.27 per share loss analysts expected. The company's revenue reached $24.7 million, significantly surpassing the anticipated $6.5 million. This indicates a strong financial performance above market predictions for the genome editing firm.
Editas Medicine Q4 2025 Financial Report: Loss of $5.6M, Revenue $24.7M - News and Statistics
Editas Medicine Inc. reported a Q4 2025 loss of $5.6 million, or 6 cents per share, surpassing Wall Street's expectation of a 27-cent loss. The company's revenue for the quarter reached $24.7 million, significantly exceeding the forecasted $6.5 million. For the full year, Editas Medicine reported a loss of $160.1 million ($1.80 per share) on revenues of $40.5 million.
Gene edit slashes cholesterol 90% in tests; human trial next for Editas
Editas Medicine (EDIT) reported its Q4 and full-year 2025 financial results, alongside significant progress on its lead gene-editing candidate, EDIT-401. Preclinical studies for EDIT-401 showed over 90% reduction in LDL-C, with an IND/CTA submission expected by mid-2026 and first-in-human trials commencing later in 2026. The company also announced a cash runway extending into Q3 2027, supported by reduced operating expenses and a strategic focus on in vivo gene editing.
Editas Medicine stock rises 2% after Q4 earnings and revenue beats
Editas Medicine (NASDAQ:EDIT) reported strong Q4 results, surpassing analyst expectations with a narrower loss of $0.06 per share and revenue reaching $24.74 million. This positive performance was primarily driven by reduced R&D and general and administrative expenses, and the company expects its cash to fund operations into Q3 2027 while progressing its lead candidate, EDIT-401, towards clinical trials.
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Editas Medicine reported its financial results for the fourth quarter and full year 2025, highlighting significant progress in its in vivo gene editing programs. The company's lead candidate, EDIT-401, for heterozygous familial hypercholesterolemia (HeFH), is on track for IND/CTA submission by mid-2026 and initiation of its first-in-human clinical trial, with early proof-of-concept data expected by year-end 2026. Editas also emphasized a strong cash position, extending its cash runway into the third quarter of 2027.
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Editas Medicine reported its financial results for the fourth quarter and full year 2025, highlighting progress in its gene editing pipeline. The company's lead candidate, EDIT-401 for heterozygous familial hypercholesterolemia (HeFH), is on track for IND/CTA submission by mid-2026 and aims to initiate a first-in-human clinical trial with early proof-of-concept data expected by year-end 2026. Editas Medicine maintains a strong cash position, with a runway into the third quarter of 2027.
Cowen Maintains Buy on EDIT Editas Medicine, Inc. March 2026
Cowen & Co. reiterated a "Buy" rating for Editas Medicine, Inc. (EDIT) on March 9, 2026, following the release of the company's Q4 results. Despite a small post-reiteration pullback, the maintained rating signifies Cowen's ongoing confidence in Editas's programs and potential for outperformance, though no new price target was issued. Investors are advised to combine this analyst rating with their own research, clinical milestone tracking, and risk assessment for informed decision-making.
Editas Medicine SVP Parison sells $957 in stock
Amy Parison, SVP and CFO of Editas Medicine (NASDAQ:EDIT), sold 474 shares of company stock for a total of $957 on March 3, 2026. This transaction was executed under a pre-arranged automatic sales plan to cover tax obligations from vested restricted stock units. Following the sale, Parison directly owns 15,434 shares, and InvestingPro analysis suggests the stock is currently undervalued.
Editas Medicine SVP Parison sells $957 in stock
Amy Parison, SVP and Chief Financial Officer at Editas Medicine, Inc., sold 474 shares of common stock for $957 on March 3, 2026. The sale was executed under a pre-arranged automatic sales plan to cover tax obligations from vested restricted stock units. Following the transaction, Parison directly owns 15,434 shares of Editas Medicine.
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,394 Shares
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill sold 5,394 shares of the company's stock on March 3rd at an average price of $2.02, totaling $10,895.88. Following the sale, O'neill directly owns 263,693 shares, representing a 2.00% reduction in his position. The company has a current market cap of approximately $213.8 million and a "Moderate Buy" consensus analyst rating with an average price target of $5.00.
EDIT Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Editas Medicine Inc (EDIT), including its income statement, balance sheet, and cash flow statement. It highlights the company's weak financial health with a low profitability score, declining revenue, and negative net income, alongside its strong liquidity and low debt-to-equity ratio. The analysis also covers key metrics like free cash flow, EPS, R&D spending, and calculates an estimated cash runway of 8 months.
